Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-878P is a **pseudogene** of the **U6 small nuclear RNA (snRNA) family**[3]. U6 snRNA itself is an essential part of the spliceosome, the complex responsible for intron removal during pre-mRNA splicing in eukaryotes[5][7]. U6-derived pseudogenes like RNU6-878P result from genomic duplications or retrotranspositions but do not encode functional RNA or protein products. These pseudogenes lack promoter elements or accumulate mutations preventing their expression or function. While the broader U6 family is highly conserved due to its key catalytic role in splicing, the pseudogene copies are generally considered non-functional genomic elements[5][7]. There is no evidence that RNU6-878P is expressed or has a direct biological, pathological, or therapeutic relevance at this time[3][4].\n\nSummary: \nRNU6-878P is a non-coding, non-functional pseudogene related to the U6 snRNA; it is not considered a therapeutic target, biomarker, or disease-relevant molecule, and does not interact with any drugs[3][4][5].
None known
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 878, pseudogene (RNU6-878P).